- Home
- SQM vs EXEL Comparison
SQM vs EXEL Comparison
Compare SQM & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQM
- EXEL
- Stock Information
- Founded
- SQM 1968
- EXEL 1994
- Country
- SQM Chile
- EXEL United States
- Employees
- SQM N/A
- EXEL N/A
- Industry
- SQM Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SQM Industrials
- EXEL Health Care
- Exchange
- SQM Nasdaq
- EXEL Nasdaq
- Market Cap
- SQM 11.3B
- EXEL 9.4B
- IPO Year
- SQM 1993
- EXEL 2000
- Fundamental
- Price
- SQM $40.00
- EXEL $33.12
- Analyst Decision
- SQM Hold
- EXEL Buy
- Analyst Count
- SQM 8
- EXEL 17
- Target Price
- SQM $45.56
- EXEL $35.67
- AVG Volume (30 Days)
- SQM 1.0M
- EXEL 2.7M
- Earning Date
- SQM 03-04-2025
- EXEL 02-11-2025
- Dividend Yield
- SQM 0.53%
- EXEL N/A
- EPS Growth
- SQM N/A
- EXEL 441.02
- EPS
- SQM N/A
- EXEL 1.55
- Revenue
- SQM $4,766,643,000.00
- EXEL $2,081,598,000.00
- Revenue This Year
- SQM N/A
- EXEL $20.64
- Revenue Next Year
- SQM $20.61
- EXEL $2.76
- P/E Ratio
- SQM N/A
- EXEL $21.40
- Revenue Growth
- SQM N/A
- EXEL 17.31
- 52 Week Low
- SQM $32.24
- EXEL $20.02
- 52 Week High
- SQM $51.90
- EXEL $37.59
- Technical
- Relative Strength Index (RSI)
- SQM 54.83
- EXEL 44.92
- Support Level
- SQM $38.39
- EXEL $32.44
- Resistance Level
- SQM $41.37
- EXEL $33.65
- Average True Range (ATR)
- SQM 1.01
- EXEL 1.21
- MACD
- SQM 0.02
- EXEL -0.18
- Stochastic Oscillator
- SQM 57.03
- EXEL 21.44
About SQM Sociedad Quimica y Minera S.A.
Sociedad Quimica y Minera de Chile is a Chilean commodities producer with significant operations in lithium (primarily used in batteries for electric vehicles and energy storage systems), specialty and standard potassium fertilizers, iodine (primarily used in X-ray contrast media), and solar salts. The company extracts these materials through its high-quality salt brine deposits and caliche ore. SQM is developing a hard rock lithium project in Australia and expanding its lithium refining assets in China.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.